{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial., Devos, Timothy, Geukens Tatjana, Schauwvlieghe Alexander, Ari\'ebn Kevin K., Barbezange Cyril, Cleeren Myriam, Compernolle Veerle, Dauby Nicolas, Desmecht Daniel, Grimaldi David, et al. , Trials, 2020 Nov 27, Volume 21, Issue 1, (2020)\par \par }